Lilly completes $7.8B acquisition of Centessa Pharmaceuticals
- Jul 13
- 9 min read
Updated: Jul 14
Deal Snapshot
Eli Lilly (NYSE: LLY) has agreed to acquire Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage biotech developing orexin receptor 2 (OX2R) agonists for narcolepsy and other sleep-wake disorders. Announced on March 31st, 2026, the deal closed less than three months later, on June 24th, 2026.
Under the agreed terms, Lilly pays $38.00 per share in cash upfront, implying an equity value of approximately $6.3 billion and a 40.5% premium over Centessa's 30-day volume-weighted average share price. Shareholders also receive a non-transferable contingent value right (CVR) worth up to $9.00 per share (roughly $1.5 billion) paid out only if Centessa's lead drug candidate hits specific FDA approval milestones. Summing up cash and CVR, the deal's total potential equity value goes up to $7.8 billion. Accounting for Centessa's cash and debt on hand, the implied transaction value comes out to approximately $7.6 billion at the maximum CVR payout.
Acquirer: Eli Lilly and Company
Target: Centessa Pharmaceuticals plc
Announced: March 31, 2026
Closed: June 24, 2026
Equity value: up to $7.8B
Deal value: ~$7.6B
Premium (30 day VWAP): 40.5%
1 day premium: 70.4%
Financial advisors to Centessa: Centerview Partners, Jefferies
Financial advisor to Lilly: Morgan Stanley
Legal counsel: Goodwin Procter (Centessa), Kirkland & Ellis (Lilly)
Players
Eli Lilly (NYSE: LLY) is a 150-year-old pharmaceutical company that focuses on turning scientific research into medicines across diabetes, obesity, oncology, immunology, and neuroscience. Its recent growth has been driven overwhelmingly by its GLP-1 franchise, Mounjaro and Zepbound, which the company has used to fund an active string of acquisitions expanding its pipeline in areas like neuroscience, where Centessa fits.
Centessa Pharmaceuticals (Nasdaq: CNTA) is a clinical-stage biotechnology company pioneering in a new class of therapeutics in orexin-based neuroscience. Its lead candidate, cleminorexton, is an oral OX2R agonist (drugs that activate a brain receptor involved in regulating sleep and wakefulness) in late-stage development for narcolepsy and idiopathic hypersomnia (two conditions that cause excessive, uncontrollable daytime sleepiness), with earlier-stage follow-on candidates targeting broader neuroscience indications. Like most clinical-stage biotechs, Centessa has no approved products or revenue yet, funding its research through capital raises.
Eli Lilly
Equity Value: $1.1T
Enterprise Value: $1.1T
Revenue (FY2025): $65.2B
Employees: ~48,000
P/E ratio: ~40x
EV/EBITDA: ~28-30x
EV/Sales: ~15x
HQ: Indianapolis, Indiana
Centessa Pharmaceuticals
Equity Value (before deal): $4.1B
Equity Value: up to $7.8B
Enterprise Value: $7.6B
Revenue: pre-commercial, no product sales
Net loss (LTM): $250.7M
Cash on hand: $276.6M
Total debt: $118.6M
Shares outstanding: ~155M
Valuation multiples: not meaningful, given no revenue and negative EBITDA
HQ: Altrincham, Cheshire, UK (management operations based in Boston, MA)
The Backstory
A Centessa board member also sits on Lilly's board, and in May 2025 she introduced Lilly's Chief Scientific Officer to Centessa's then-CEO. The two companies signed a confidentiality agreement in June 2025, and discussions continued through the summer as Lilly reviewed data on Centessa's lead program.
Centessa was not short on suitors, it had separately been in talks with three other major pharmaceutical companies over the prior year, though none of those conversations advanced. One of them approached the Centessa board directly in January 2026 with acquisition interest, but walked away in March, before making any formal offer, citing concerns that Centessa's market valuation was too rich given how early-stage its pipeline still was.
As for Lilly, in February 2026, it opened with an offer of $36.00 per share in cash, offer that Centessa's board rejected claiming it was inadequate, but agreed to give Lilly deeper access to due diligence. Lilly returned in March with a new proposal: $38.00 upfront plus a CVR, avoiding increasing the cash upfront by much while sharing the potential up-side of the deal. Centessa pushed for more cash up front, however, Lilly held firm on that number but raised the CVR ceiling from $7.00 to $9.00 per share. About a week after that offer, both sides finalized terms, and the deal was signed and announced days later.
Deal Rationale
For Lilly, the deal is about buying speed and depth in an area of medicine it believes is underexploited. This field had been on Lilly's radar for years, but Centessa had built the broadest portfolio of drug candidates, including its lead drug in mid-stage testing for narcolepsy and a related sleep disorder, plus a couple of earlier-stage backups that could extend into other neurological conditions. Rather than spend years building this expertise from scratch internally, Lilly frames the deal as a way to pursue that opportunity with urgency rather than waiting years for in-house research to catch up.
For Centessa, the logic is less about growth and more about resolving risk. As a clinical-stage biotech with no approved products and no revenue, Centessa's board had to weigh a certain, immediate cash payout against the alternative of remaining independent, which implied continuing to fund trials through dilutive capital raises, absorbing the regulatory and commercialization risk of getting a drug to market alone, and hoping the stock eventually reflected that value. The board's own disclosed reasoning relied heavily on this trade-off, otherwise shareholders would remain exposed to clinical and financing risk with no guarantee that Centessa's share price would ever approach the deal's value on a standalone basis.
Lilly is effectively paying today for a platform that may not generate meaningful revenue for several years. While strategically compelling, the acquisition leaves little room for clinical disappointment. Centessa's shareholders trade a speculative, capital-needing future for cash today plus upside optionality through the CVR.
Deal Structure
As Centessa is incorporated in the UK as a public limited company (plc), the deal required approval both from Centessa shareholders and formal sanction from the High Court of Justice of England and Wales. Both approvals were secured in June 2026, clearing the way for closing.
As mentioned before, consideration is 100% cash, divided into two pieces. Shareholders received $38.00 per share upfront at closing, and on top of that, they received one non-transferable Contingent Value Right (CVR) per share, paying out up to $9.00 more across three separate FDA milestones:
$2.00 if Centessa's lead compound (or a related molecule) receives its first FDA approval for any indication, before December 31, 2029
$5.00 if the FDA approves a treatment for idiopathic hypersomnia, within five years of closing
$2.00 if the FDA approves a treatment for narcolepsy type 2, within five years of closing
The CVR is non-transferable, therefore, holders cannot sell it separately from their decision to accept the deal, it simply rides alongside the cash payout and pays out later if milestones are met.
On the financing side, Lilly funded the acquisition through a mix of cash on hand, new borrowings, and its commercial paper program. Finally, deal carried no financing condition, meaning Lilly's obligation to close wasn't contingent on successfully raising the funds.
Valuation Discussion
At 70.4% over its last unaffected closing price, Lilly's premium sits well above recent comparable deals in the sector. Johnson & Johnson's $14.6B acquisition of Intra-Cellular Therapies in January 2025 carried a 39% premium on the same one-day basis, and Novartis' $12B purchase of Avidity Biosciences in October 2025 carried a 46% premium. Both of those deals also targeted neuroscience-focused biotechs, making them reasonable points of comparison.
The deal structure follows the standard playbook for pre-revenue targets. About two thirds of biotech acquisitions in 2025 included a CVR, representing over a third of total deal value on average. Here, the CVR makes up roughly 19% of the maximum potential payout ($1.5B of $7.8B), lighter than the broader market average, meaning Lilly committed more value upfront in cash rather than deferring it to future milestones.
Lilly is paying $6.3-7.8B for years of research into a specific drug mechanism, the trial data and patents behind it, and the scientists who did the work. The entire value of the deal depends on that research eventually becoming an approved drug.
Strategic Value Creation
Lilly and Centessa have not disclosed specific cost or revenue synergy targets, as the target is a pre-revenue biotech with no commercial operations to merge into the acquirer's business. What the companies have pointed to instead are the practical benefits Lilly's scale brings to Centessa's pipeline.
Lilly's neuroscience clinical trial capabilities and regulatory expertise should help cleminorexton and Centessa's earlier-stage candidates, ORX142 and ORX489, to develop faster than Centessa could have managed alone. Carole Ho, Lilly's EVP and president of Lilly Neuroscience, said Centessa's portfolio has the depth to explore the full range of orexin-related conditions, and that combining forces lets Lilly pursue that potential at greater speed and scale.
Once any of these drugs reach approval, Lilly's existing global sales force, payer relationships, and manufacturing capacity would handle their commercialization, capabilities Centessa does not have as a clinical-stage company with no products on the market. Furthermore, as Centessa's pipeline extends beyond its lead drug with relevance to other neurological and psychiatric conditions, Lilly has signaled interest in developing the platform broadly rather than treating the deal as a single-drug purchase.
What could go wrong
The premium Lilly is paying only makes sense if Centessa's drug ends up capturing a meaningful share of the sleep disorder market it's targeting, but that's not guaranteed. Centessa's main drug is not the most advanced treatment of its kind in development. A rival company, Takeda, has a similar drug currently awaiting an FDA decision expected sometime in Q3 2026, ahead of Centessa's, which is still earlier in the testing process. Alkermes, another competitor, is also moving quickly with its own version. If Takeda's drug reaches the market first and establishes itself as the default option for doctors and patients, Centessa's drug could end up fighting for a smaller slice of the market, making the 40.5% premium harder to justify.
Regarding the $9.00 per share in additional CVR payments on the table, that money only gets paid out if Centessa's drugs clear specific FDA approval deadlines. Centessa's own financial advisors assigned real probabilities that some of these milestones would not be met in time, which implies that there is a meaningful chance shareholders receive less than the full amount, or none of it.
Underneath both of those risks sits a more basic one: none of Centessa's drug candidates have been approved by health regulators anywhere yet. They have only completed smaller-scale trials and still need more definitive studies before approval is possible. If those studies disappoint or regulators ask for more evidence, both Lilly’s commercial assumptions and Centessa shareholders' odds of collecting the CVR, weaken at the same time.
There's also a risk specific to what Lilly is buying. Centessa's real value sits in a relatively small team of scientists and the years of accumulated know-how behind its drug candidates. If key researchers leave after the deal, whether due to a culture mismatch or simply the uncertainty that could follow the acquisition, the pipeline could advance more slowly than Lilly is counting on.
Timeline
Mid-2025: Informal contact between Lilly and Centessa leads to a confidentiality agreement and early due diligence
February 2026: Lilly makes an initial offer of $36.00 per share, Centessa's board rejects it as inadequate
March 2026: Lilly returns with $38.00 per share plus a CVR, terms finalized after further negotiation
March 31, 2026: Deal signed and announced
May 21, 2026: U.S. antitrust clearance obtained
June 12, 2026: Centessa shareholders approve the deal
June 22, 2026: High Court of England and Wales sanctions the transaction
June 24, 2026: Deal closes & Centessa delisted from Nasdaq
Overall Assessment
By the numbers, Lilly paid a high price. A 70.4% premium is well above what recent comparable neuroscience deals commanded, for an asset still in Phase 2a testing rather than something already approved. Whether that turns out to be expensive depends entirely on execution, not on the price itself.
Strategically, the logic holds up. Lilly is buying the broadest pipeline in a therapeutic area it clearly wants to lead, funded by cash generated elsewhere in the business, and doing so with urgency rather than building the capability in-house over several years. That's a reasonable use of a strong balance sheet.
The main risk of the deal relies on the fact that this is still a bet on unproven science in a competitive race, not a business with revenue already in hand. Everything else, the premium, the CVR structure, the synergy case, is secondary to whether the drug itself works and arrives in time to matter.
Sources
Centessa Pharmaceuticals plc. (2026, April 17). Preliminary proxy statement (Schedule PREM14A). U.S. Securities and Exchange Commission. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001847903&type=PREM14A
Eli Lilly and Company. (2026, March 31). Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders [Press release]. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-centessa-pharmaceuticals-advance-tr
Eli Lilly and Company. (2026, June 24). Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders [Press release]. https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-centessa-pharmaceuticals-advance
Investing.com. (2026, June 22). Lilly's $7.8 billion Centessa acquisition gets court approval. https://www.investing.com/news/company-news/lillys-78-billion-centessa-acquisition-gets-court-approval-93CH-4753682
BioSpace. (2026, March 31). Lilly wakes up sleep market with $6.3B Centessa buy to challenge Takeda. https://www.biospace.com
Takeda Pharmaceutical Company Limited. (2026, February 10). Form 6-K [SEC filing]. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1395064/000139506426000005/form6k_021026.htm
Johnson & Johnson. (2025, January 13). Johnson & Johnson strengthens neuroscience leadership with acquisition of Intra-Cellular Therapies, Inc. [Press release]. https://www.jnj.com/media-center/press-releases/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-inc
Novartis AG. (2026, February 27). Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy [Press release]. https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy
FactSet Research Systems Inc. (2026). Eli Lilly & Co. acquires Centessa Pharmaceuticals Plc [Deal summary, Deal ID 4285603MM]. FactSet Mergers.
Eli Lilly and Company. (2026). Form 10-K [Annual report]. U.S. Securities and Exchange Commission. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478&type=10-K